Fate Therapeutics announced this week that Rudolf Jaenisch, founding member of the Whitehead Institute for Biomedical Research and a professor of biology at the Massachusetts Institute of Technology, has joined the company's team of scientific founders.
In connection with the appointment, Fate Therapeutics also announced this week that it has completed an exclusive license agreement with the Whitehead Institute covering discoveries in the area of cell reprogramming.
Jaenisch is a founding member of the Whitehead Institute. He has coauthored more than 300 research papers, is a member of the National Academy of Sciences, and has received awards including the First Peter Gruber Foundation Award in Genetics (2001), Robert Koch Prize for Excellence in Scientific Achievement (2002), Brupbacher Foundation Cancer Award (2003), Vilcek Prize (2007), and Massry Prize (2008).
Bio-Matrix Scientific Group announced this week that it has named Feng Lin and Marilyn Panahi to the newly created positions of laboratory/scientific director and quality assurance director, respectively.
Lin was previously a senior research scientist for R&D at Inovio Biomedical.
Prior to joining Bio-Matrix, Panahi was quality manager for Therapheresis.